Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.

Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Ahmed S, Deeba RE, Tang G, Aljawai Y, Lee HC, Patel KK, Gaballa MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH, Pasvolsky O

Open source

DOI: 10.1111/bjh.70642
Published: 2026 Sep
Container: British journal of haematology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/bjh.70642,
  title = {Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.},
  author = {Marcoux C and Milton DR and Tanner MR and Bashir Q and Srour S and Saini N and Lin P and Ramdial J and Nieto Y and Ahmed S and Deeba RE and Tang G and Aljawai Y and Lee HC and Patel KK and Gaballa MR and Kebriaei P and Thomas SK and Orlowski RZ and Champlin RE and Shpall EJ and Qazilbash MH and Pasvolsky O},
  year = {2026},
  journal = {British journal of haematology},
  doi = {10.1111/bjh.70642},
  url = {https://doi.org/10.1111/bjh.70642}
}

RIS

TY  - JOUR
TI  - Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.
AU  - Marcoux C
AU  - Milton DR
AU  - Tanner MR
AU  - Bashir Q
AU  - Srour S
AU  - Saini N
AU  - Lin P
AU  - Ramdial J
AU  - Nieto Y
AU  - Ahmed S
AU  - Deeba RE
AU  - Tang G
AU  - Aljawai Y
AU  - Lee HC
AU  - Patel KK
AU  - Gaballa MR
AU  - Kebriaei P
AU  - Thomas SK
AU  - Orlowski RZ
AU  - Champlin RE
AU  - Shpall EJ
AU  - Qazilbash MH
AU  - Pasvolsky O
PY  - 2026
JO  - British journal of haematology
DO  - 10.1111/bjh.70642
UR  - https://doi.org/10.1111/bjh.70642
ER  -

APA

C, M., DR, M., MR, T., Q, B., S, S., N, S., P, L., J, R., Y, N., S, A., RE, D., G, T., Y, A., HC, L., KK, P., MR, G., P, K., SK, T., RZ, O., RE, C., EJ, S., MH, Q., & O, P. (2026). Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.. British journal of haematology. https://doi.org/10.1111/bjh.70642

Source records

pubmed · retrieved 2026-09-27T00:39:51.830Z
europe-pmc · retrieved 2026-09-27T00:39:51.841Z